ArticleNature genetics2025
DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution.
Abstract read
In one paragraph
Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Consolidated Evidence and New Frontiers of Liquid Biopsy in Lung Cancer: A Narrative Review.Cells · 2026Review
- Pattools‑implemented methylation vector analysis reveals aberrant subtype‑specific methylation in lung cancer across tissue and plasma cfDNA.Clinical and translational medicine · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib.The journal of liquid biopsy · 2026Article
- Regulating the dormancy of cancer stem cells: a novel approach to preventing cancer relapse.Cell death & disease · 2026Review
- Mitochondrial remodeling and metabolic reprogramming drive long-term salinity adaptation inmSystems · 2026Article
- Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026Review
- Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma.Frontiers in oncology · 2026Article
- NOP2-mediated 5-methylcytosine Regulates Lipid Metabolism Reprogramming to Prime Tumors for Ferroptosis in Bladder Cancer Progression.International journal of biological sciences · 2026Article
- Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma.medRxiv : the preprint server for health sciences · 2025Article
- DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution.Nature genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Francisco Gimeno-Valiente *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Carla Castignani *Cancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Elizabeth Larose CadieuxCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-9320-8040
Nana E MensahCancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Xiaohong LiuMedical Genomics, University College London Cancer Institute, London, UK.
Kezhong ChenCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Olga ChervovaMedical Genomics, University College London Cancer Institute, London, UK.
Takahiro KarasakiCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6863-2360
Clare E WeedenCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Corentin RichardCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Siqi LaiDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carlos Martínez-RuizCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4817-0565
Emilia L LimCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Alexander M FrankellCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0341-7878
Thomas B K WatkinsCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Georgia StavrouCancer Metastasis Laboratory, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8427-5233
Ieva UsaiteCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Wei-Ting LuCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1405-4806
Daniele MarinelliCancer Metastasis Laboratory, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6002-363X
Sadegh SaghafiniaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Gareth A WilsonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Pawan DhamiGenomics Research Platform, R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-5408-1833
Heli VaikkinenGenomics Research Platform, R&D Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Jonathan SteifDepartment of Microbiology and Immunology, Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Robert E HyndsCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-2170-8791
Martin HirstDepartment of Microbiology and Immunology, Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
Crispin HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Andrew FeberDivision of Surgery and Interventional Science Medical Genomics, University College London, London, UK.
Özgen DenizCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0001-7268-1923
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1212-1259
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9537-4045
TRACERx Consortium
Stephan BeckMedical Genomics, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-5290-2151
Jonas DemeulemeesterCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-2660-2478
Miljana TanićMedical Genomics, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-3102-776X
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4299-3018
Peter Van LooCancer Genomics Laboratory, The Francis Crick Institute, London, UK. pvanloo@mdanderson.org.ORCID http://orcid.org/0000-0003-0292-1949
Nnennaya KanuCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. n.kanu@ucl.ac.uk.ORCID http://orcid.org/0000-0001-7232-1952
Funding
Regional Government of Valencia | Conselleria d'Educació, Investigació, Cultura i Esport (Conselleria d'Educació, Investigació, Cultura i Esport de la Generalitat Valenciana) APOSTD/2021/168Wellcome Trust CC2008Wellcome Trust CC2041
Abstract
Aberrant DNA methylation has been described in nearly all human cancers, yet its interplay with genomic alterations during tumor evolution is poorly understood. To explore this, we performed reduced representation bisulfite sequencing on 217 tumor and matched normal regions from 59 patients with non-small cell lung cancer from the TRACERx study to deconvolve tumor methylation. We developed two metrics for integrative evolutionary analysis with DNA and RNA sequencing data. Intratumoral methylation distance quantifies intratumor DNA methylation heterogeneity. M
Indexed as
Carcinoma, Non-Small-Cell LungDNA MethylationLung NeoplasmsCpG IslandsDNA Copy Number VariationsEpigenesis, GeneticEvolution, MolecularGene Expression Regulation, NeoplasticHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.